{"slug": "lucaid-agentic-multimodal-ai-for-lung-cancer-precision-pathology", "title": "LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology", "summary": "Researchers developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology, which integrates nine modules covering the full routine workflow from quality control to predictive biomarker scoring. In prospective clinical validation, LUCAID achieved 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists, with analysis modules achieving F1 scores of 0.82-0.95 against large-scale expert ground-truth annotations.", "body_md": "arXiv:2608.23803v1 Announce Type: new\nAbstract: Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.", "url": "https://wpnews.pro/news/lucaid-agentic-multimodal-ai-for-lung-cancer-precision-pathology", "canonical_source": "https://arxiv.org/abs/2608.23803", "published_at": "2026-08-26 04:00:00+00:00", "updated_at": "2026-08-26 04:14:01.065341+00:00", "lang": "en", "topics": ["artificial-intelligence", "machine-learning", "computer-vision", "ai-agents", "ai-research"], "entities": ["LUCAID", "arXiv"], "alternates": {"html": "https://wpnews.pro/news/lucaid-agentic-multimodal-ai-for-lung-cancer-precision-pathology", "markdown": "https://wpnews.pro/news/lucaid-agentic-multimodal-ai-for-lung-cancer-precision-pathology.md", "text": "https://wpnews.pro/news/lucaid-agentic-multimodal-ai-for-lung-cancer-precision-pathology.txt", "jsonld": "https://wpnews.pro/news/lucaid-agentic-multimodal-ai-for-lung-cancer-precision-pathology.jsonld"}}